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A REDUCTION IN THE RNA BINDING PROTEIN TIA1 PROTECTS 
AGAINST NEURODEGENERATION, RESCUES BEHAVIORAL 
DEFICITS AND PROLONGS SURVIVAL 
 
ANANTBIR SINGH RANDHAWA 
ABSTRACT 
 
 RNA binding proteins (RBPs) have been found to be frequently involved in 
neurodegenerative diseases (Ash 2014). Mutations in RBPs cause amyotrophic lateral 
sclerosis (ALS), spinocerebellar ataxia, frontotemporal dementia (FTD) and myopathies 
(Ash 2014), and recent studies suggest that aggregation of RBPs are a pathological 
feature frequently encountered in tauopathies (Vanderweyde 2016). Emerging studies on 
neurodegenerative diseases are now showing an increasingly important role for tau in 
regulating the biology of RBPs. In this study, we examine findings that show that 
reducing the RBP T-cell intracellular antigen 1 (TIA1) in vivo not only protects against 
neurodegeneration, but also prolongs the survival rate in transgenic P301S tau mice. 
Furthermore, the reduction of TIA1 decreases the number and size of granules co-
localizing with stress granule markers, and inhibits the accumulation of tau oligomers, 
although at the expense of an increased number of neurofibrillary tangles. However, 
despite the observed increase in neurofibrillary tangles, this TIA1 reduction still manages 
to increase neuronal survival, rescue behavioral deficits and prolong lifespan. The in vivo 
data presented in this study suggests an important role for TIA1 in mediating toxicity and 
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provides evidence that RBPs orchestrate a pathway to tau aggregation and the resulting 
neurodegeneration.  
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TABLE OF CONTENTS 
 
TITLE ___________________________________________________________i 
COPYRIGHT PAGE _______________________________________________ii  
READER APPROVAL PAGE ______________________________________ iii 
DEDICATION ___________________________________________________ iv 
ABSTRACT ______________________________________________________v 
TABLE OF CONTENTS __________________________________________ vii 
LIST OF FIGURES _______________________________________________ ix 
LIST OF ABBREVIATIONS ________________________________________xi 
INTRODUCTION _________________________________________________1 
Tau Protein: Location, Synthesis, and Degradation ………………………1 
Tauopathies ……………………………………………………………….3 
Stress Granules ……………………………………………………………9 
Neuroinflammation ……………………………………………………...12 
Purpose …………………………………………………………………..19 
RESULTS ______________________________________________________ 20 
TIA1 haploinsufficiency reduces cytoplasmic translocation of TIA1 and 
SG formation …………………………………………………………………… 20 
 viii 
TIA1 reduction protects against synaptic and neuronal loss in PS19 
mice………………………………………………………………………………22 
TIA1 reduction alleviates cognitive impairment and extends lifespan in 
PS19 mice………………………………………………………………………..26 
TIA1 reduction initially decreases tau phosphorylation ……………….. 29 
TIA1 reduction accelerates accumulation of Neurofibrillary Tangles 
(NFT) while decreasing levels of soluble tau oligomers ………………………. 31 
DISCUSSION ___________________________________________________ 36 
            Further Direction ………………………………………………………...40 
REFERENCES __________________________________________________ 41  
CURRICULUM VITAE ___________________________________________56  
  
 ix 
LIST OF FIGURES 
 
 
Figure Title Page 
1 Tau expression 2 
2 Development of 
tau pathology 
7 
3 Development of 
pathological stress 
granule 
10 
4 IL-1β 
immunoreactivity 
in brainstem and 
spinal cord of 
human P301S tau 
transgenic mice 
and age-matched 
controls 
14 
5 COX-2 
immunoreactivity 
in brain and spinal 
cord of human 
P301S tau 
transgenic mice 
15 
6 Double-labeling 
immunostaining 
for OX-42 or OX-
6 (brown) and tau 
phosphorylated at 
S422 (antibody 
AP422) (red) in 
brainstem and 
spinal cord of 
human P301S tau 
transgenic mice 
and age-matched 
controls 
17 
7 TIA1 reduction 
decreases 
cytoplasmic stress 
granules in PS19 
mice while 
20 
 x 
increasing nuclear 
TIA1 
8 TIA1 reduction 
rescues synaptic 
and axonal loss in 
PS19 mice 
23 
9 TIA1 reduction 
protects against 
neurodegeneration 
in PS19 mice 
25 
10 TIA1 reduction 
improves memory 
and prolongs 
lifespan in PS19 
mice 
28 
11 TIA1 reduction 
leads to an age-
dependent 
increase in tau 
phosphorylation 
32 
12 TIA1 reduction 
shifts the 
biochemical and 
structural 
properties of tau 
aggregation 
35 
13 Model for 
regulation of tau 
oligomerization 
39 
 
  
 xi 
LIST OF ABBREVIATIONS 
 
AD     Alzheimer’s Disease 
ALS     Amyotrophic Lateral Sclerosis 
cdk5     Tau Protein Kinase II 
COX-2    Cyclooxygenase-2 
FTD     Frontotemporal Dementia 
GSK-3     Tau Protein Kinase I 
IHC     Immunohistochemistry 
IL1-β     Interleukin-1β 
LEnt     Lateral Entorhinal Cortex 
M1     Primary Motor Area 
MBD     Microtubule-Binding Domains 
MT     Microtubule 
NeuN     Neuron-Specific Nuclear Protein 
NFT     Neuro-Fibrillary Tangles 
p38     MAP Kinase 
PHF     Paired Helical Filaments 
RBP     RNA Binding Protein 
SG     Stress Granules 
TIA1     T-cell Intracellular Antigen 1
 1 
INTRODUCTION 
Tau Protein: Location, Synthesis, and Degradation 
 Tau is a structural microtubule-associated protein that is located in the cytosol, 
present primarily in the axons of neurons, and is involved in axonal transport. Tau protein 
also organizes the assembly and stabilization of microtubules for the purposes of axonal 
transport, by binding to microtubules. Tau binds to microtubules through specific 
microtubule-binding domains (MBDs) (Hernández 2007). These MBDs have a 
characteristic region of three tandem repeats of 31 or 32 amino acid residues located in 
the C-terminal of the tau protein (Goedert 1989). MBDs, although important, are not the 
only regions that affect tau-binding ability: two proline-rich regions, which when 
phosphorylated, also affect the microtubule-binding ability of Tau (Hernández 2007).  
 The tau gene is a single-copy gene in the human genome and is localized on 
chromosome 17 (Andreadis 1992), where it occupies over 100kb and contains 16 exons 
(Neve 1986). The tau gene undergoes transcription to yield nuclear RNA, which is then 
alternatively spliced and translated into different tau isoforms with different numbers of 
exons. In the adult brain, for example, six isoforms of tau have been found (Goedert 
1989). The difference in isoforms exists due to the presence or absence of a fourth 31-
amino acid repeat, which is coded by exon 10 within the MBD region, as well as due to 
the presence of zero, one or two inserts coded by exons 2 and 3 in the amino-terminal of 
tau protein. Since exon 10 encodes part of the region that is involved in the binding of tau 
to microtubules, the alternative splicing scheme produces isoforms that either have three 
or four MBDs (Hernández 2007). The significance of tau isoforms becomes relevant in 
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the development of tauopathies, which are pathologies resulting from the aggregation of 
tau protein. 
  
Figure 1. Tau expression. A single tau gene located on human chromosome 17 is transcribed 
into the corresponding nuclear RNA that, after alternative splicing, yields several tau messenger 
RNAs (mRNAs). These mRNAs, upon translation, originate the different tau isoforms. The 
complexity of the tau isoforms can then be increased by posttranslational modification, such as 
phosphorylation. A scheme of tau isoforms present in the central nervous system is indicated, 
showing the microtubule binding domains (MBD) on the tau molecule. The tubulin binding 
repeats are indicated in black (except exon 10, which is shown dashed) within the tau molecule. 
Exons 2 (green) at the amino-terminal region and exon 3 (blue) are also shown (Hernández 2007). 
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 Proteins have a half-life that is determined by the presence of signals that control 
its degradation. One such signal that is significant is the PEST signal (peptide sequence 
rich in Proline (P), Glutamic Acid (E), Serine (S), Threonine (T)), a specific N-terminal 
sequence (Dantuma 2002) that is present on tau molecules. More importantly, however, 
is the evidence that suggests that tau is degraded by the ubiquitin-proteasome system 
(UPS), after the tau protein is ubiquitinated. The ubiquitin-conjugating enzymes that are 
involved in the first steps of tau degradation by the UPS were first characterized after the 
purification of phosphorylated tau that was obtained from AD brains (Hernández 2007). 
Tau’s phosphorylation is necessary for the addition of ubiquitin by the E3 Ubiquitin 
ligase, CHIP. As a result, the absence of CHIP in mice leads to the accumulation, but not 
aggregation, of hyperphosphorylated tau (Dickey 2006). Another mechanism by which 
the degradation of tau has been shown to be mediated involves proteases, specifically 
caspases (Rohn 2002). Tau cleavage by caspases generates a truncated protein that 
assembles more rapidly and more extensively into tau filaments in vitro, compared to 
wild-type tau (Gamblin 2003), suggesting that the activation of caspases and subsequent 
cleavage of tau in AD brains may lead to the formation of Neuro-Fibrillary Tangles 
(NFTs). 
Tauopathies 
 Tauopathies are neurodegenerative disorders that are caused due to the deposition 
of abnormal tau protein isoforms in neurons. Clinically, tauopathies encompass 20 
pathological entities, which include Alzheimer’s disease, the most common tauopathy, 
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progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), frontotemporal 
dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease (PiD), 
post-encephalitic parkinsonism (PEP) dementia pugilistica, Down’s syndrome, 
Parkinson’s disease complex (PDC) of Guam and argyrophilic grain disease (Williams 
2006). 
Tau phosphorylation/dephosphorylation by kinases and phosphatases 
respectively, play an important role in the development of tauopathies, with 
serine/threonine residues being the most common sites for modifications. Tau, a 
phosphoprotein (Ihara 1986), has multiple isoforms. The longest isoform, which contains 
441 residues (figure 1), contains 79 serine or threonine phosphorylation sites. These sites 
can be further subdivided into two types: those that can be modified by proline-directed 
kinases like tau protein kinase I (GSK3), tau protein kinase II (cdk5), MAP kinase (p38), 
and JNK (Hernández 2007); and those that can be modified by non-proline-directed 
kinases like PKA, PKC, CaM kinase II, MARK kinases (Imahori 1997; Goedert 1997; 
Correas 1992; Drewes 1992; Baudier 1987; Scott 1993; Hanger 1992; Lucas 2001) or 
CKII. 
 Apart from phosphorylation modifications at serine/threonine residues, tau 
proteins have been found to be phosphorylated at tyrosine residues as well. Tyrosine 
kinase fyn has been found to modify tau proteins at tyrosine residues (Lee 2004), and it 
has been shown that missense mutations of tau, which are present in FTDP-17, could 
potentially increase the binding of tau to fyn, further facilitating the phosphorylation of 
tau by fyn (Bhaskar 2005). 
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 Phosphatases are enzymes that dephosphorylate their protein substrates. There 
exist several such phosphatases that are able to desphosphorylate tau protein, however 
only certain phosphatases are able to dephosphorylate abnormally hyperphosphorylated 
tau, like PP1, PP2, and PP2B (Gong 1994). PP2C on the other hand, although capable of 
dephosphorylating tau when it is phosphorylated by PKA in vitro, is unable to 
dephosphorylate hyperphosphorylated tau that is isolated from AD brains (Gong 1994). 
PP2A is a phosphatase that binds to tau in its tubulin binding region. It has been observed 
that mutations in this region decrease the capacity of PP2A to bind to tau, increasing tau 
phosphorylation, a feature that has been observed in FTDP-17 patients that have similar 
mutations (Goedert 2000). 
 The literature referenced above implicates phosphorylated tau as being a major 
contributing factor to various types of tauopathies and raises the possibility of designing 
therapy that is aimed at inhibiting the phosphorylation of tau by tau kinases, especially 
GSK-3 (Bhat 2004). For example, previous studies have shown that lithium inhibits 
GSK-3, and it may serve as a therapy for modulating tau hyperphosphorylation and 
neurodegeneration in AD (Alvarez 1999). Furthermore, lithium has also been shown to 
have a beneficial effect on FTDP-17 mouse models (Perez 2003). Apart from lithium 
treatment, phosphatase enzyme regulation also shows potential as possible therapy for 
tauopathies. Increasing the activity of PP2A, the main tau phosphatase, may regulate the 
level of tau phosphorylation. PP2A is in turn regulated by two proteins, I1-PP2A and I2-
PP2A, and inhibiting these regulatory proteins will result in an increase in the activity of 
PP2A, which could result in a decrease in tau phosphorylation (Chen 2006). 
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 It is well established that phosphorylated tau has a reduced affinity towards 
microtubules and thus a reduced ability to promote microtubule assembly, which is one 
of the hallmark functions of tau protein (Lindwall 1984). Furthermore, tau 
phosphorylation can impair axonal transport in neurons by occupying sites on 
microtubules that are used by kinesin motor proteins (Vershinin 2007). However, it has 
not yet been established whether or not the phosphorylation of tau could result in a gain-
of-function mechanism or whether it only disrupts functions of unmodified tau. 
Regardless of what the case might be, the abnormal deposition of protein in neurons is a 
feature that is shared by many neurodegenerative diseases, such as tauopathies. 
 An underlining feature of tauopathies is the presence of abnormal tau aggregates. 
About 30 years ago, it was discovered that tau was the main component of paired helical 
filaments (PHFs) (Grundke 1986), and that purified tau has the ability to form fibrillar 
polymers resembling PHFs that are found in the brain of AD patients (Montejo de 
Garcini 1986). There are many factors that may promote tau polymerization and eventual 
aggregation, but aggregation of tau in AD does not seem to depend on the tau isoforms 
(Lee 2001), even though the number of mRNAs of tau isoforms seem to increase 
significantly in AD-affected areas (Glatz 2006). Instead, certain phosphorylation profiles 
seem to regulate the aggregation of tau into PHFs, making the role of phosphorylation in 
the self-assembly of tau a fundamental question in the study of AD, and other 
tauopathies. It has been suggested that the phosphorylation of some specific tau sites, 
occurring in the PHF core-forming MBD domain, are a prerequisite for tau assembly 
(Bancher 1989). Another question that warrants inquiry is the molecular structure of tau 
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protein in PHFs. The current view is that in order to give rise to fibrils, the pathological 
protein aggregation must involve the β-sheet structure (Serpell 1997). Since the sites 
where tau is phosphorylated are the very sites that form the core of PHFs, it is strongly 
suggestive of the fact that phosphorylation controls assembly, even though no 
mechanistic model has been proposed that highlights the interplay between 
phosphorylation and assembly. 
 
  
 
Figure 2. Development of tau pathology. The development of tau pathology is characterized by 
an increase in phosphorylated tau and by the presence of NFT. Here is shown tau pathology in a 
transgenic mouse overexpressing GSK-3b and FTDP-17 tau. Transgenic tau accumulates in the 
somatodendritic compartment, but only in old mice the number of phosphorylated tau-positive 
neurons increase (center panel). Immunohistochemistry carried out with T14 antibody, which 
recognizes only human transgenic tau (left panel), and immunoflorescence carried out with the 
phosphorylated tau antibody AT8 (center panels) is shown for double transgenic mice. The right 
panel shows Thiazin Red-positive neurons (NFT-like structures) that were found in hippocampal 
pyramidal neurons only at the age of 18 months. It is still possible to partially reverse tau 
pathology in advanced stages of the disease. Thus, when lithium (a GSK-3 inhibitor) is 
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administered to these mice, phosphorylated tau decreases, although tau aggregated in NFT-like 
structures does not revert to its previous state (Engel 2006). 
 
 To further explore tau-related pathologies, a number of transgenic mouse models 
have been developed with the objective of reproducing aspects of tau pathology that are 
frequently encountered in neurodegenerative diseases like AD and FTDP-17. For 
example, the P301S tau gene mutation transgenic mouse model causes rapid early-onset 
FTDP-17, and could be instrumental in providing insight into the onset of tauopathies 
since it exhibits many of the characteristics of human tauopathies. These include the 
formation of filaments that are made up of hyperphosphorylated tau protein, and is 
accompanied by neurodegeneration that leads to nerve cell loss (Bellucci 2004). 
Homozygous animals from this line develop a motor phenotype dominated by paraparesis 
at 6 months of age, along with abundant neuronal inclusions made up of 
hyperphosphorylated mutant human tau protein, present in the brains and spinal cords of 
these animals (Bellucci 2004). Another P301S transgenic mouse model that is useful in 
exploring the tau pathologies encountered in FTDP-17 has been developed and shows 
that the PS19 line developed synaptic pathology and microgliosis in hippocampus at 3 
months of age followed by synaptic dysfunction at 6 months of age before neuronal loss 
was noted, along with NFT formation (Yoshiyama 2007). In this review, we will present 
data from the P301S transgenic mouse model to explore the various aspects of tau 
pathologies. 
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Stress Granules 
 Stress granules (SGs) are an aggregation of RNA-binding proteins that are formed 
when the cell is under going stress. These RNA-binding proteins, including T-cell 
intracellular antigen 1 (TIA-1), are the core nucleating factors of SGs, and are found in 
pathological lesions of neurological conditions, such as Alzheimer’s Diseases. Cellular 
stress causes protein translation to switch from capdependent to cap-independent RNA 
translation, which causes the cell to shut down the synthesis of non-housekeeping 
proteins and to maintain its synthesis of proteins that protect against stress, like heat 
shock proteins (Kedersha 2007; Buchan 2009). This translational stress switch also leads 
to the translocation of RNA-binding proteins (RBPs) to the cytoplasm, and consolidates 
these RBPs to mRNA transcripts to form RNA-protein complexes that are termed stress 
granules (SGs) (Vanderweyde 2012). One of the primary stress granule protein includes 
the TIA-1, which is an RBP that will be reviewed in this paper. 
 As illustrated in figure 3, SG formation is initiated by the phosphorylation of 
eIF2α at the Serine 51 (S51) location. This phosphorylation is mediated by a number of 
kinases, one of the important ones being Protein Kinase R (PKR), which is a double-
stranded RNA-dependent kinase that responds to viral infection, heat shock and UV 
irradiation (Peter 2014). mRNA transcripts that are targeted to SGs initially exist as 
capped mRNAs bound to translation pre-initiation 40S ribosomal complexes containing 
other translation factors, like elongation factors EF-4A, E and G, eIF3 and poly-A 
binding protein. Thus, this eIF2α phospho-S51 signal inhibits the formation of the eIF2, 
GTP and tRNAMet initiation complex for protein translation (Kedersha 1999), leading to 
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the dissociation of the ribosomal units. These mRNA transcripts are then bound by RBPs 
TIA-1, TIAR, TTP and G3BP1. SGs are formed by the consolidation of these RBPs 
through the association of the glycine-rich prion-related domains (Kedersha 2000). 
 
  
 
Figure 3. Development of pathological stress granules  
RNA binding proteins facilitate many aspects of RNA metabolism including both nuclear and 
cytoplasmic functions in mRNA splicing, maturation and cellular localization. Under stress 
conditions, responsive kinases phosphorylate eIF2α leading to the disassembly of the polysome 
and the induction of SG formation. SGs are nucleated through the binding of core RBPs to 
mRNA and their self-assembly through the association of prion-related domains. Maturation of 
SGs follows with the recruitment of secondary RBPs. In disease, prolonged stress, mutations that 
favor the pro-aggregation state or the inability to recover and disassemble the RBPs leads to the 
deposition of abundant, large pathological stress granules (Peter 2014). 
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 With the maturation of SGs, additional RBPs are recruited both from the nucleus 
as well as from the cytoplasm. During this “secondary maturation,” a number of disease-
relevant RBPs including TDP-43 (Colombrita 2009; Liu-Yesucevitz 2010), FUS 
(Dormann and Haass, 2011), ataxin 2 (Hart and Gitler, 2012) and SMN1 (Hua and Zhou, 
2004) associate with SGs. These RBPs further bring additional transcripts that are 
sequestered in the maturing SG. 
 The formation of SGs in response to a stressor is a transient event, and these SGs 
tend to dissipate within 1-3 hours after the stressor has been removed (Kedersha 1999). 
The dissipation of SGs is mediated by the dephosphorylation of eIF2α S51. Growth arrest 
and DNA damage-inducible protein 43 (GADD34) associates with Protein Phosphatase 1 
(PP1) and recruits it to eIF2α for the dephosphorylation of Serine 51 (Brush 2003). 
GADD34 is normally maintained in the cell under basal conditions, but it is induced upon 
exposure to various stressors (Brush 2008), effectively establishing a feedback 
mechanism to limit the phosphorylation of eIF2α and allow the cell to recover from 
transient stress. 
 Recently, it has been reported that SGs are associated with the pathological 
inclusions that are prevalent in multiple neurodegenerative diseases such as Huntington’s 
disease, Creutzfeldt-Jakob disease (CJD), amyotrophic lateral sclerosis (ALS), and 
frontotemporal dementia linked to ubiquitin (FTLD-U) (Waelter 2001; Goggin 2008). 
The interactions between SGs and tau are or particular interest to this study since tau can 
bind to RNA, and RNA is known to promote the assembly of tau to form PHFs (Kampers 
1996). Furthermore, because there is evidence of a high concentration of RNA in SGs, 
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there is a possibility that the formation of SGs have an impact on the aggregation of tau, 
to form the inclusions that are so frequently encountered in tauopathies (Vanderweyde 
2012). 
 It has been observed that tau pathology, such as that observed in many 
neurodegenerative diseases, is associated with very large stress granules. This raises the 
possibility that stress granules, which are generally transient structures, form abnormally 
stable structures in these neurodegenerative diseases (Peter 2014). It is thus hypothesized 
that these large stable SGs are pathological and they contribute to the neurodegenerative 
process, perhaps by sequestering RBPs. 
Neuroinflammation 
 Mice that are transgenic for human P301S tau protein display many of the same 
characteristics that we see in human tauopathies, including the formation of abundant 
filaments made up of hyperphosphorylated tau protein and neurodegeneration leading to 
nerve cell loss. These changes, however, do not occur in isolation. In fact, they are 
accompanied by marked neuroinflammation. Many nerve cells in the brainstem and 
spinal cord that are tau-positive are strongly immunoreactive for interleukin-1β (IL1-β) 
and cyclooxygenase-2 (COX-2), indicative of induction and overproduction of pro-
inflammatory cytokines and enzymes (Bellucci 2004). It is important to consider the sub-
topic of neuroinflammation when talking about neurodegenerative diseases like 
Alzheimer’s Disease, because cytokines cause an increase in the levels of 
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hyperphosphorylated tau, which lead to increased microglial activation, which in turn 
leads to even more release of cytokines. 
 In recent years, a lot of interest has developed into studying the inflammatory 
processes that occur in neurodegenerative diseases. However, comparatively little is 
known and has been studied about the inflammatory processes in diseases with only tau 
deposits. Bellucci 2004 reports that brain and spinal cords from 5-month-old human 
P301S tau transgenic mice exhibit a strong inflammatory reaction, which is characterized 
by the production of IL1-β and the induction of COX-2, accompanied by the activation of 
microglial cells. 
 Upon the staining and immunoblotting for IL1-β and COX-2, numerous IL1-β-
positive cells with neuronal morphology were present throughout the central nervous 
system of 5-month-old human P301S tau transgenic mice (Bellucci 2004), and they were 
particularly pronounced in the brainstem and spinal cord (Figure 4; A and C). In control-
mice that were age-matched with the transgenic mice, only a few nerve cells were found 
to be weakly IL1-β-immunoreactive (Figure 4; B and D).
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Figure 4. IL-1β immunoreactivity in brainstem and spinal cord of human P301S tau 
transgenic mice and age-matched controls. A and B: Brainstem of 5-month-old transgenic (A) 
and control (B) mice. C and D: Spinal cords of 5-month-old transgenic (C) and control (D) mice. 
Note the strong staining of some nerve cell bodies and processes (arrows in C). Scale bars: 150 m 
(B, also representative for A); 71 m (D, also representative for C) (Bellucci 2004). 
 
Furthermore, in transgenic mice, numerous COX-2-immunoreactive nerve cell 
bodies were found to be present in the cerebral cortex, hippocampus, brainstem, 
cerebellum, and spinal cord (Figure 5; A, C, D, E, F). On the other hand, only a 
proportion of nerve cells were positive for COX-2 in control mice (Figure 5; B). 
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Figure 5. COX-2 immunoreactivity in brain and spinal cord of human P301S tau transgenic 
mice. Strongly stained nerve cells and processes (arrows) in brainstem (A), spinal cord (C), 
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cerebral cortex (D), hippocampus (E), and cerebellum (F) of 5-month-old human P301S tau 
transgenic mice. B: COX-2 immunoreactivity in brainstem of an age-matched control mouse. 
Note the strong staining of some nerve cell bodies and processes in A, C, D–F. Scale bars: 150 m 
(B, also representative for A); 85 m (C); 80 m (D); 170 m (E); 70 m (F) (Bellucci 2004). 
 
 While studying the affects of the inflammatory response in neurodegenerative 
diseases, it is essential to consider the activation of microglial cells. While staining for 
microglial cells in transgenic human P301S tau mice, numerous strongly OX-42 (which 
binds CD11b receptors and is useful in identify microglial cells) immunoreactive 
microglial cells were present in close proximation to AP422-positive nerve cells in 
brainstem, cerebral cortex, hippocampus, and spinal cord (Figure 6; A, C, E). Some 
displayed the morphology of activated cells with a bushy appearance and swollen cell 
bodies, along with having intensely stained, thickened, and branched processes. In the 
brains and spinal cords obtained from control mice, microglial cells were only weakly 
OX-42-immunoreactive and they displayed a sessile morphology with thin, finely 
branching processes that extent radially from small, oblong cell bodies (Figure 6; B and 
D). 
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Figure 6. Double-labeling immunostaining for OX-42 or OX-6 (brown) and tau 
phosphorylated at S422 (antibody AP422) (red) in brainstem and spinal cord of human 
P301S tau transgenic mice and age-matched controls. A, B, and E: Brainstem of transgenic 
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(A, E) and control (B) mice. C, D, and F: Spinal cord of transgenic (C, F) and control mice (D). 
Sections A to E were stained for OX-42 and phosphorylated tau. Section F was stained for OX-6 
and phosphorylated tau. Scale bars: 70 m (B, also representative for A); 90 m (D, also 
representative for C); 60 m (E, F) (Bellucci 2004). 
 
 These findings are shown here to demonstrate that the intraneuronal accumulation 
of human P301S tau protein is associated with the activation of the inflammatory process, 
including the activation of microglial cells, and thus makes for a critical segue when 
discussing neurodegenerative diseases with tauopathies. These findings mirror what has 
been described previously in AD (Akiyama 2000; McGeer 1989; Haga 1989), and in 
other tauopathies, as well as in diseases with intracellular filamentous deposits such as 
Parkinson’s disease (McGeer 1988), demential with Lewy bodies (Mackenzie 2000), 
multiple system atrophy (Ishizawa 2004), and ALS (Kawatama 1992). The lesions that 
are seen in AD are evidence of localized inflammation, with reactive microglia being 
present in neuritic plaques and in and around neurofibrillary lesions. 
 Microglia have long been known to migrate to regions where there is nerve cell 
damage, and are known to contribute to the elimination and “cleaning-up” of dead cells 
through their phagocytic activity (Gonzalez-Scarano 1999). Inflammation then, may not 
be the root cause of disease as seen in the human P301S tau transgenic mice, however, it 
may play an important role in the series of events leading up to neurodegeneration. 
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Purpose 
 This review presents data that helps to define the effects of reducing TIA1, an 
RNA-binding protein, on neurodegeneration, memory function and survival in the P301S 
mouse model of tauopathy. 
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RESULTS 
TIA1 haploinsufficiency reduces cytoplasmic translocation of Tia1 and SG formation 
  By using the PS19 transgenic mouse line, which overexpresses the human 
P301S 1N4R tau under the control of the mouse prion promoter, Apicco 2017 were 
able to investigate whether the reduction of endogenous TIA1 protects against the 
progression of tauopathy in vivo (Yoshiyama 2007). PS19 mice were bred with 
TIA1-/- mice to yield tauopathy mice that possess either one or two copies of the 
TIA1 allele, which will be referred to as P301S TIA1+/- and P301S TIA1+/+ mice, 
respectively (Phillips 2004). Immunoblot analysis of endogenous TIA1 protein levels 
in the brain confirmed that TIA1 protein expression was reduced by >50% in 3-
month-old P301S TIA1+/- mice compared to P301S TIA1+/+ mice (Figure 7; a, b). 
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Figure 7. TIA1 reduction decreases cytoplasmic stress granules in PS19 mice while 
increasing nuclear TIA1. a, Immunoblot of TIA1 from total brain lysates of 3-month-old P301S 
Tia1 +/+ and P301S Tia1 +/– mice. b, Quantification of relative TIA1 protein level from a, 
normalized to β-actin. **P = 0.0095 by unpaired Student’s t test (n = 5 per group). c, IHC of 
DAPI (blue), TIA1 (green) and PABP (red) in 9-month-old layer II LEnt. Scale bar, 5 µm. d, 
Quantification of the number of cytoplasmic puncta per cell co-positive for SG markers TIA1 and 
PABP from c (arrows). **P < 0.01 by one-way ANOVA with Tukey’s post hoc tests (n = 4 mice 
per group, at least 20 cells imaged per mouse). e, f, Quantification of total nuclear (e) and 
cytoplasmic (f) TIA1 immunofluorescence from c. ***P < 0.001 by unpaired Student’s t test. g, i, 
IHC of the RNA transport granule marker Staufen (g, red) and the processing-body marker 
DCP1A (i, green) in 9-month-old P301S Tia1 +/+ and P301S Tia1 +/– frontal cortex. Scale bars, 
10 µm. h, j, k, Quantification of total Staufen immunofluorescence (h), total DCP1A 
immunofluorescence (j) and number of cytoplasmic DCP1A granules (k) per cell in g and i. 
***P < 0.001 by unpaired Student’s t test (n = 4 mice per group, at least 20 cells imaged per 
mouse). Error bars represent mean ± s.e.m. Immunoblots in a are cropped (Apicco 2017). 
 
 Next, it was investigated whether P301S TIA1+/- mice displayed reduced 
cytoplasmic TIA1 granules. Immunohistochemistry (IHC) analysis of hippocampal 
neurons in P301S TIA1+/- mice revealed there was >50% reduction of cytoplasmic TIA1 
granules compared to P301S TIA1+/+ mice. Furthermore, it was noted that there was 
similar reduction in cytoplasmic TIA1 puncta co-localizing with the SG marker PABP 
(Figure 7; c and d). In contrast to P301S TIA1+/+ mice that exhibited a depletion of 
nuclear TIA1, P301S TIA1+/- mice were protected against such a loss of nuclear TIA1 
(Figure 1; e and f). Apicco 2017 also found that the IHC for markers of other types of 
 22 
RNA granules further demonstrated that a TIA1 reduction increased immunofluorescence 
levels and puncta for the transport granule marker Staufen and the processing-body 
marker DCP1A (Figure 1; g-k). Thus, these data illustrate that the heterozygous knockout 
of TIA1 selectively inhibits the formation of cytoplasmic TIA1 granules and prevents the 
loss of nuclear TIA1 in vivo. 
TIA1 reduction protects against synaptic and neuronal loss in PS19 mice 
 It has previously been established that PS19 mice exhibit progressive neuronal 
loss between 6 and 12 months of age, which is preceded by presynaptic degeneration 
(Yoshiyama 2007). It is thus imperative to investigate whether TIA1 reduction also 
reduces synaptic and neuronal loss in vivo. To do this, Apicco 2017 examined the CA3 
region of the hippocampus, due to the presence of a high density of axon terminals and 
neuronal cell bodies in this region, in addition to this region being well characterized in 
synaptic and neuronal loss in PS19 mice. It was found that compared to non-transgenic 
littermates, 6-month-old P301S TIA1+/+ mice showed reduced immunofluorescence of 
synaptophysin, a presynaptic terminal protein, which was consistent with prior reports 
(Figure 8; a and b) (Yoshiyama 2007). However, synaptophysin immunofluorescence 
was seen to be rescued in P301S TIA1+/- mice when compared to P301S TIA1+/+ mice 
(Figure 8; a and b), indicative of reduced presynaptic degeneration. Hence, reducing 
TIA1 appears to have a protective effect against presynaptic degeneration in P301S tau 
mice. 
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Figure 8. TIA1 reduction rescues synaptic and axonal loss in PS19 mice. a, IHC of 
NeuN (green) and synaptophysin (SYP, red) in the CA3 region of 6-month-old non-transgenic 
(WT Tau) and PS19 (P301S Tau) hippocampus. Scale bar, 20 μm. b, Quantification of relative 
SYP expression from a. *P = 0.0135, **P = 0.0067 by two-way ANOVA with Tukey’s post hoc 
test (n = 15–31 images per group, from at least 6 mice per group). c, Immunoblot of total tau 
(Tau13) detected in MT-bound (pellet, P) and unbound (supernatant, S) fractions in 6- and 9-
month-old WT and P301S cortex. d, Quantification of the relative ratio of MT-bound to MT-
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unbound tau at 9 months in a (normalized to the average level in P301S Tia1 +/+ mice, which we 
set equal to 1). *P = 0.0138 by Student’s t test (n = 4 per group). Error bars denote mean ± s.e.m. 
Immunoblots in c are cropped (Apicco 2017). 
 
 As mentioned previously, tau binds and stabilizes microtubules (MTs), which 
helps promote axonal outgrowth and in turn, fast axonal transport. Apicco 2017 
investigated whether the reduction of TIA1 would protect binding of tau to MTs in these 
mice. Centrifugation in RAB (reassembly) buffer was used to separate MT-bound (pellet, 
P) and unbound (supernatant, S) fractions, as described previously by Yoshiyama 2007, 
and as expected, tau was observed to progressively accumulate in the MT-unbound (S) 
fraction of P301S TIA1+/+ mice between the ages of 6 and 9 months, which indicates the 
dissociation of tau from MTs (Figure 8; c). On the other hand, in the MT-unbound (S) 
fraction of P301S TIA1+/- mice, significantly less tau was observed. This led to a 
threefold increase in the ratio of MT-bound (P) to unbound (S) tau in mice 9 months of 
age (Figure 8; c and d). These data indicate that a reduction in TIA1 is associated with the 
stabilization of MTs. 
 Total number of neurons in the hippocampus (CA3) and lateral entorhinal cortex 
(LEnt) of P301S TIA1 +/+ and P301S TIA1 +/- mice were quantified. It has been 
previously reported by Yoshiyama 2007 that neurons in the hippocampus of P301S TIA1 
+/+ mice were reduced by 6 months of age. Apicco 2017 reports that the number of 
Nissl+ and NeuN (neuron-specific nuclear protein)-positive nuclei increased in P301S 
TIA1 +/- mice compared to P301S TIA1 +/+ mice in both CA3 and LEnt at 9 months of 
age (Figure 9; a-c). 
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Figure 9. TIA1 reduction protects against neurodegeneration in PS19 mice. a, Representative 
Nissl stain of CA3 in 9-month-old non-transgenic (WT Tau) and P301S Tau mice. Scale bar, 
20 μm. b,c, Quantification of number of Nissl+ (b) and NeuN+ (c) neurons per field in c. 
*P < 0.05, **P < 0.01 by two-way ANOVA with Tukey’s post hoc tests (n = at least 4 per group). 
d, Representative images of cortical layers I through VI in 9-month-old non-transgenic and 
P301S cerebral cortex (primary somatosensory cortex, S1). Scale bar, 100 μm. Red asterisks and 
arrowheads denote the start of layer II and end of layer III, respectively. e, Quantification of 
average layer II/III cortical thickness in S1 from d. **P < 0.01 by two-way ANOVA with 
Tukey’s post hoc tests (n = at least 11 per group). Error bars denote mean ± s.e.m (Apicco 2017). 
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 The effect of TIA1 reduction on gross cortical atrophy was also assessed, by 
measuring the distance between the most superficial part of layer II and the deepest part 
of layer III (Figure 9; d) in the primary somatosensory cortex and LEnt of 9 month old 
P301S TIA1 +/+ and P301S TIA1 +/- mice. Results showed a 21% reduction in layer 
II/III thickness in primary somatosensory cortex and a 54% reduction in layer II/III 
thickness in LEnt in P301S TIA1 +/+ mice. P301S TIA1 +/- mice, in contrast, did not 
show any significant difference in thickness as compared to non-transgenic mice (Figure 
9; e). These data suggest that the reduction in TIA1 has a protective mechanism against 
tau-mediated neurodegeneration in vivo. 
TIA1 reduction alleviates cognitive impairment and extends lifespan in PS19 mice 
 Another important aspect was to determine whether the reduction of TIA1 
improved the behavioral phenotype of PS19 mice. Studies done previously indicate that 
PS19 mice exhibit cognitive impairment (Takeuchi 2011). Further studies revealed that 6-
month-old P301S TIA1 +/+ mice exhibited reduced spontaneous alternation in the Y-
maze spontaneous alternation task (SAT), compared to non-transgenic mice (Figure 10; 
a). This indicates an impairment in spatial working memory, as seen in PS19 mice. 
However, in P301S TIA1 +/- mice, this behavioral deficit was rescued to normal working 
memory levels (Figure 10; a); TIA1 reduction had no notable effect in non-transgenic 
mice (Figure 10; a).  
 The novel object recognition (NOR) task was also used to confirm the rescue 
effect of reducing TIA1. It was found that, as expected, P301S TIA1 +/+ mice were 
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unable to successfully distinguish between novel and familiar objects, indicating an 
impairment in recognition memory (Figure 10; b). On the other hand, P301S TIA1 +/- 
mice exhibited >65% preference for the novel object, confirming the restoration of 
functional recognition memory to levels similar to non-transgenic animals (Figure 10; b). 
It is important to note, however, that there was no difference in locomotor activity in the 
SAT or open field (OF) tasks between P301S TIA1 +/+ and P301S TIA1 +/- mice (Figure 
10; c). Both the SAT and NOR tasks depend on hippocampal function, however the SAT 
task depends on additional circuitry including the prefrontal cortex, basal forebrain and 
dorsal striatum (Lalonde 2002), whereas the NOR task additionally depends on the 
perirhinal cortex (Cohen 2015). The improvement in behavioral tasks underlined by the 
above two behavioral experiments suggests that the reduction in TIA1 confers protection 
against neurodegeneration. 
 Since the data thus far suggests that TIA1 reduction protects against tau-mediated 
neurodegeneration in vivo (Figure 9), Apicco 2017 next investigated whether TIA1 
reduction could increase the lifespan of PS19 mice. Yoshiyama 2007 previously reported 
that PS19 mice die prematurely due to motor ataxia and hindlimb paralysis, with a 
median survival of 9 months and an 80% mortality by the time mice were 12 months of 
age. P301S TIA1 +/+ mice confirmed this previous finding of lifespan phenotype (Figure 
10; d). However, P301S TIA1 +/- mice showed a marked increase in lifespan (mean 
lifespan = 11.3 months compared to a mean lifespan = 9.3 months in P301S TIA1 +/+ 
mice), along with 43.5% of them surviving to 12 months of age (Figure 10; d). 
Furthermore, 23.8% of P301S TIA1 +/- mice that were allowed to age until 15 months 
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survived, compared to 0% of P301S TIA1 +/+ mice (Figure 10; d). Apicco 2017 further 
reports that all of the non-transgenic mice in the study survived to 12 months of age (data 
not shown). These findings show us that the reduction in TIA1 extended the median 
lifespan of PS19 mice by 21.5%, thus confirming that TIA1 reduction not only confers 
behavioral protection against tau-mediated neurodegeneration, but also protects against 
premature mortality. 
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Figure 10. TIA1 reduction improves memory and prolongs lifespan in PS19 mice. a, Percent 
correct alternations in the Y-maze SAT for 6-month-old non-transgenic (WT Tau) and P301S Tau 
mice. *P = 0.0213, **P = 0.0072 by two-way ANOVA with Tukey’s post hoc test (n = 16–20 
mice per group). Error bars denote mean ± s.e.m. b, The NOR task was used to assess recognition 
memory in non-transgenic and PS19 mice. Preference index (PI) for each mouse was determined 
by dividing the amount of time spent exploring the novel object by the total amount of time spent 
exploring both objects (PI = 100 × (T novel/T novel + T familiar). *P < 0.05 by two-way ANOVA 
with Tukey’s post hoc comparisons (n = 8–15 mice per group). Error bars denote mean ± s.e.m. c, 
Total distance traveled over time in the open field (OF) locomotor activity task. Main effect of 
P301S Tau transgene by two-way ANOVA; P301S Tia1 +/+ and P301S Tia1 +/– plots are not 
statistically different, by Tukey’s post hoc test. d, Kaplan–Meier survival curve of P301S Tia1 
+/+ (n = 20, median lifespan = 9.3 months) compared to P301S Tia1 +/– (n = 23, median 
lifespan = 11.3 months) mice. ***P < 0.001 by the log-rank Mantel–Cox test. Hazard ratio (Tia1 
+/+:Tia1 +/–) = 2.411 (Apicco 2017). 
TIA1 reduction initially decreases tau phosphorylation  
 Hyperphosphorylated tau is found in AD and FTD, where it leads to tau 
aggregation and subsequent pathology. Apicco 2017 compared the age-dependent 
accumulation of phosphorylated tau in P301S TIA1 +/+ and P301S TIA1 +/- mice by 
IHC. Not surprisingly, it was found that detectable levels of CP13 (S202)- and AT8 
(S202/T205)- phosphorylated tau had accumulated in the hippocampus of P301S TIA1 
+/+ mice by the age of 3 months. However, little to no phosphorylated tau was found to 
have been accumulated in the cortex or the cerebellum of P301S TIA1 +/+ mice at 3 
months of age, which shows consistency with the expected progression of disease in 
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PS19 mice. As expected, reduced levels of CP13- and AT8- phosphorylated tau was 
found in the hippocampi of P301S TIA1 +/- mice, compared to P301S TIA1 +/+ mice at 
3 months of age. This suggests that reducing TIA1 plays a role in the delayed onset of 
pathology in PS19 mice. 
 Levels of AT8-, CP13-, and PHF1- phosphorylated tau were then measured to 
determine how TIA1 reduction affected tau phosphorylation at later stages of disease, 
namely at 6 and 9 months of age. Surprisingly, reduction in TIA1 led to an increase in 
immunofluorescence for AT8- and CP13- phosphorylated tau at 6 and 9 months of age. 
Furthermore, a reduction in TIA1 also led to an increase in the number of PHF1+ 
inclusions in LEnt and CA3 at 9 months of age (Figure 11; a and b). Interestingly, in 
P301S TIA1 +/+ mice, whereas almost 20% of PHF1+ inclusions were found to co-
localize with cytoplasmic TIA1, only 5% of PHF1 inclusions contained TIA1 in P301S 
TIA1 +/- mice (Figure 11; c and d). It is also noteworthy that P301S TIA1 +/- mice 
showed marked rescue of TIA1 localization in the nucleus, with TIA1 being largely 
restricted to the nucleus even in PHF1+ neurons (Figure 11; c). Thus, these findings 
reveal that the reduction in TIA1 initially decreases the level of phosphorylated tau 
pathology in PS19 mice, however, at the same time exhibits an age-dependent increase in 
phosphorylated tau at later stages of disease. 
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TIA1 reduction accelerates accumulation of Neurofibrillary Tangles (NFT) while 
decreasing levels of soluble tau oligomers 
 Alongside age-dependent increases in tau phosphorylation, an increase in NFTs 
was also seen in P301S TIA1 +/- mice. Apicco 2017 found that throughout the 
hippocampus and the temporal cortex, 9-month-old P301S TIA1 +/+ mice developed 
extensive Gallyas silver- and thioflavine S (ThioS)- positive tangles (Figure 11; e-h). 
Furthermore, they also found that P301S TIA1 +/- mice exhibited increased numbers of 
Gallyas silver-positive neurons in both the primary motor area (M1), as well as in LEnt 
(Figure 11; f). Additionally, TIA1 reduction increased the level of ThioS fluorescence in 
P301S TIA1 +/- mice (Figure 11; g and h). There was no significant difference in the 
number of Gallyas silver-positive tangles between P301S TIA1 +/+ and P301S TIA1 +/- 
mice in the CA3 region of the hippocampus, potentially due to a ‘ceiling effect’ caused 
by significant pathology in the region, compared to other brain areas (Figure 11; f). 
However, even though an equal number of NFTs were found in the CA3 region of P301S 
TIA1 +/+ and P301S TIA1 +/- mice at the age of 9 months, no relationship was found 
between tangles and neuronal loss in either P301S TIA1 +/+ or P301S TIA1 +/- mice. 
From this, it can be deduced that the neuroprotection received from the reduction of TIA1 
in PS19 mice occurs independently from NFTs, which is consistent with previous studies, 
which suggested that NFTs are not directly related to neuronal loss that is frequently 
encountered in tauopathies (Rocher 2010; Santacruz 2005; Calignon 2010). 
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Figure 11. TIA1 reduction leads to an age-dependent increase in tau phosphorylation. a, 
DAPI (blue) and IHC for PHF1 (phospho-S396/S404; red) phospho-tau in LEnt of 9-
 33 
month-old P301S Tia1 +/+ and P301S Tia1 +/– mice. Scale bar, 10 μm. b, Quantification 
of number of PHF1+ cells in a. *P = 0.0483, **P = 0.0028 by unpaired Student’s t tests 
(n = 6 per group). c, Confocal images of PHF1+ cells in P301S Tia1 +/+ and P301S Tia1 
+/– LEnt. Scale bar, 2 μm. d, Quantification of the percentage of PHF1+ cells with TIA1 
co-localization in c. **P = 0.0074 by Student’s t test (n = 4 per group). e, Representative 
images of Gallyas silver-stained NFT in 9-month-old P301S Tia1 +/+ and P301S Tia1 
+/– mice. Scale bar, 40 μm. f, Quantification of number of Gallyas silver-positive tangles 
in the frontal cortex (primary motor area, M1), LEnt and CA3. *P < 0.05 by unpaired 
Student’s t tests (n = 4 per group); ns, not significant. g, Representative images of LEnt 
from 9-month-old non-transgenic and PS19 mice stained with thioflavine S (ThioS). 
Scale bar, 20 μm. Red insets denote high-magnification images of ThioS+ tangles in 
P301S Tia1 +/+ and P301S Tia1 +/– LEnt. h, Quantification of ThioS fluorescence in g. 
*P = 0.0213 by Student’s t test (n = 6 per group). Error bars denote mean ± s.e.m (Apicco 
2017). 
 
 Since an improved functional phenotype has been observed in P301S TIA1 +/- 
mice, despite the increased pathology of tau, Apicco 2017 have hypothesized that TIA1 
reduction alters the biochemical and structural properties of tau aggregates, producing tau 
that is less toxic. This hypothesis seems especially plausible because neurons that contain 
NFT-like inclusions are still found to be functional and different types of tau aggregates 
exhibit different patterns of pathophysiology when injected into tauopathy mice (Rocher 
2010; Santacruz 2005; Calignon 2010; Sanders 2014; Kuchibhotla 2014). By using 
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biochemical fractionation methods, different tau species with distinct structural properties 
can be identified that are apparent upon separation of Tris-buffered saline (TBS)- 
extractable (S1), sarkosyl-soluble (S3) and sarkosyl-insoluble (P3) fractions (Sahara 
2013). Upon a second, high-speed spin of the S1 fraction, further fractions are produced, 
namely a supernatant (S1c) and an insoluble pellet (S1p). This insoluble pellet (S1p) 
contains oligomeric tau species that correlate with neurodegeneration in rTg4510 mice, 
whereas the sarkosyl-insoluble (P3) fraction contains mostly fibrillar, 
hyperphosphorylated (CP13+PHF1+) tau (Berger 2007). Apicco 2017 used a similar 
approach using 6- and 9-month-old P301S TIA1 +/+ and P301S TIA1 +/- mice, which 
revealed that tau accumulates progressively in both the S1p and P3 fractions of P301S 
TIA1 +/+ mice (Figure 12; a-c), suggesting accumulation of oligomeric tau and NFTs 
respectively. Predominant bands were found under nonreducing conditions at 64, 140, 
and 170kDa when the S1p fraction underwent immunoblotting for total tau, confirming 
the presence of tau monomers as well as tau oligomers (Figure 12; a). Although a 
reduction in TIA1 showed an increase in the level of tau in the P3 fraction, as well an 
increase in NFTs, as seen earlier (Figure 11), it did however drastically reduce the levels 
of all tau isoforms that were detected in the S1p fraction (Figure 12; a and b). This result 
suggests that a TIA reduction prevents the accumulation of oligomeric tau while 
promoting the accumulation of fibrillar tau, all by shifting the pathway of tau 
aggregation. 
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Figure 12. TIA1 reduction shifts the biochemical and structural properties of tau 
aggregation. a, Immunoblot for total tau (Tau13) in the S1p (top) and P3 (bottom) fractions of 6- 
and 9-month-old P301S Tia1 +/+ and P301S Tia1 +/– cortex. Each lane corresponds to a 
different mouse from the cohort. b, c, Quantification of tau accumulation in the S1p (b) and P3 
(c) fractions in a. IB, immunoblot. *P = 0.08, **P = 0.0018 by unpaired Student’s t tests (n = 3 
per group). Error bars denote mean ± s.e.m. Immunoblots in a are cropped (Apicco 2017). 
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DISCUSSION 
 It is now well established that the dysfunction of RBPs is often implicated in 
multiple neurodegenerative diseases (Li 2013; Wolozin 2012). The results shown above 
indicate that TIA1 and other RBPs accumulate in unison with oligomeric tau in an animal 
model of tauopathy. Noteworthy is the fact that upon the reduction of TIA1, a selective 
reduction in tau oligomers is observed, with an accompanying increase in sarkosyl-
insoluble tau fibrils. Furthermore, not only did this reduction in oligomeric tau confer 
strong neuroprotection, it also led to a behavioral rescue effect, and increased longevity 
in the P301S TIA1 +/- mice. These results demonstrate a vital role for TIA1 in 
orchestrating the pathway for tau aggregation and the resulting neurodegeneration. 
 The classic model that has been proposed to explain protein aggregation in 
neurodegenerative diseases puts forth the idea that proteins with hydrophobic regions 
tend to aggregate through a process of random association with little to no biological 
function (Dobson 2003). Although this model might accurately reflect the mechanism 
which is driving the aggregation of amyloids, such as β-amyloids, that accumulate in the 
extracellular compartment, recent studies lend support to an alternative model, one in 
which the biological functions of RBPs and other nuclear proteins have been implicated. 
Such proteins are said to contain low-complexity domains whose biophysical properties 
promote aggregation under normal physiological conditions (Li 2012). At high 
concentrations, recombinant RBPs self-aggregate and form liquid-like droplets that can 
phase-separate and they cycle between liquid and solid states in response to temperature 
(Patel 2015; Nott 2015; Molliex 2015; Lin 2015). This dynamic process leads to the 
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formation of membraneless organelles, which include SGs, transport granules and P-
bodies, in addition to nuclear structures, such as nucleolus and promyelocytic leukemia 
(PML) bodies (Feric 2016; ; Maziuk 2017; Taylor 2016; Banani 2016). 
 The studies by Apicco 2017 demonstrated that tau plays a role in the translational 
stress response, which promotes the formation of SGs, allowing the neuron to 
preferentially synthesize certain proteins to cope with the stress, while simultaneously 
shutting down the synthesis of other non-essential proteins (Vanderweyde 2016). Even 
the internalization of extracellular tau during propagation seems to be capable of inducing 
SG formation (Brunello 2016). Tau can inhibit protein synthesis due to somatodendritic 
mislocalization, which provides a mechanism through which tau could interact with 
RBPs, RNA and ribosomes (Meier 2016). Recent discoveries show that tau undergoes 
liquid-liquid phase separation in the presence of RNA, providing a potential mechanism 
for the interaction of tau with SGs (Zhang 2017). Therefore, this points towards the 
possibility that since there is an abundance of RNA in SGs, it might be sufficient to 
stimulate oligomerization and liquid-liquid phase-separation of tau. This further provides 
reason enough to explain why neurons have tau mislocalize to the somatodendritic arbor 
and aggregate there during cellular stress. Together, these observations and discoveries 
lend support to the idea that SGs contribute to the pathophysiology of tauopathy. 
 It is important to make note of the fact that SGs have not been well characterized 
in vivo in the context of disease. Thus, in vivo equivalents will be referred to as pSGs. 
The nature of pSGs could differ from classic SGs since the composition and dynamics of 
pSGs observed in P301S mice are still yet to be determined. 
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The study directly addresses the process of tauopathy in the aging brain in vivo. 
The accumulation of tau oligomers and fibrils can be regulated by TIA1, which is 
suggestive of a more general role for RBPs. Although the process of how tau aggregation 
occurs is known to proceed through a series of steps, which include misfolding, 
oligomerization and fibrillization, the mechanism by which RBPs might interact with and 
influence these intermediates is unknown (Zempel 2014). Interestingly, when Apicco 
2017 used electron microscopy, they demonstrated something that had not been 
anticipated beforehand- TIA1 stabilized pre-fibrillar tau aggregates and inhibited their 
assembly into larger fibrils. Furthermore, by using mass spectrometry techniques, when 
oligomeric fractions from diseased brains were analyzed, it was found that P301S TIA1 
+/+ samples were enriched with RBPs compared to wild-type and P301S TIA1 +/- 
samples. These observations demonstrate that when tau associates with RBPs, the 
association is not just limited to TIA1. These results allow the model of tau aggregation 
to be extended further, by proposing that tau oligomers selectively associate with RBPs, 
introducing the possibility that tau oligomers may promote pSGs and the translational 
stress response. As noted earlier, tau phase-separates in the presence of RNA (Zhang 
2017), which lends support to the importance of tau oligomers in its interactions with 
TIA1 and RNA. 
 One of the leading issues faced while translating findings from simplified models 
with recombinant proteins or cultured cells to mouse models and human patients is the 
time frame; neurodegenerative diseases related to aging, for instance, arise in vivo after 
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an extended period of time and evolve at a much slower pace when compared to in vitro 
studies. By reducing TIA1 in PS19 mice, Apicco 2017 showed a reduction in the pSG 
response. As seen in the results, a reduction in TIA1 also correlated with an increase in 
neuronal survival, improvements in  
memory function and the prolongation of life. In TIA1 haploinsufficiency, reduction in 
tau oligomers and the corresponding increase in tau fibrils is suggestive of the fact that 
RBPs that are associated with pSGs (including TIA1) stabilized tau oligomers, ultimately 
leading to the pathological response that is the result of their accumulation (Figure 13). 
On the other hand, when the pSG response is absent, the overexpressed tau accumulates 
as tau fibrils. The absence of the pSG response also leads to a better behavioral outcome 
in the PS19 mice, suggesting that an association of tau with pSGs might actually have a 
larger role to play in neurodegeneration in humans, which increases the potential for 
therapy. 
Figure 13. Model for regulation of tau oligomerization by TIA1 (Apicco 2017). 
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Further Direction 
 Apart from the ones mentioned in this study, RBPs like TIA1 carry out many 
other functions in the cell, such as regulating RNA localization and utilization in the 
soma and dendritic arbor, and processes like splicing and RNA polymerase procession in 
the nucleus (Ling 2013; Darnell 2013). This raises the possibility that the reduction of 
TIA1 and its accompanying protection against tauopathy may occur through various 
mechanisms. 
 This study ventures into relatively new territory, one in which tauopathies are 
placed on a spectrum that is associated with RBPs. Apicco 2017 have demonstrated that 
RBPs regulate the pathophysiology of tau, which suggests a new model for the 
emergence of tauopathy. The results discussed in this study propose a model that begins 
to link the biophysics of liquid-liquid phase-separation with the course of 
neurodegenerative disease, which could take months to years. Encouragingly, this model 
provides a potential mechanistic site for entry of RBPs into the process of tau aggregation 
and the resultant tau-mediated neurodegeneration, opening up a wide array of targets for 
therapeutic intervention in the treatment of AD and various other tauopathies. 
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